solution. In addition, FDA will make internal changes to intensify its ability to surface and address crucial issues and to support high-priority critical path research efforts.

Challenge and Opportunity on the Critical Path to New Medical Products (March 2004)



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement